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Abstract
Introduction
Resuscitative endovascular balloon occlusion of the aorta (REBOA) is rapidly evolving as an emergency haemorrhage control 
technique. It has wide potential applicability in remote and austere settings, and following military trauma where prolonged 
field care might be required. However, rapid confirmation of balloon delivery is a challenge which relies on estimates derived 
from anatomical measurements or trans-abdominal ultrasound. In addition, confirmation of adequate balloon expansion is 
difficult. Intravascular ultrasound (IVUS) offers a solution to these two issues, making REBOA a deliverable therapy in the 
pre-hospital and early hospital settings.
Methods
In an animal model of severe ballistic trauma, following characterisation of the technique, an IVUS-REBOA device was con-
figured, combining a peripheral angioplasty balloon and a digital coronary IVUS catheter. This was introduced via a sheath into 
the femoral vessel over a conventional angioplasty guide wire.
Results
Real time IVUS imaging allowed confirmation of delivery of the balloon to the aorta, and also demonstrated full apposition 
once deployed. Furthermore, using ChromaFlo imaging, the device confirmed loss of pulsatile flow in the aorta after deploy-
ment, correlating with loss of transduced femoral pressure traces. Post-mortem examination confirmed correct anatomical 
balloon placement.
Summary
For the first time, in a porcine pilot study, we have demonstrated that IVUS-REBOA is feasible and confirms both correct bal-
loon placement and haemostasis. It has potential to offer advantages to REBOA operators especially during the pre-hospital and 
retrieval phases, and in the early phase of hospital delivered damage control resuscitation at remote locations. 
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Introduction
Haemorrhage is the primary cause of death following injuries 
sustained in conflict. Effective medical systems which deliver 
early resuscitation and control of bleeding are vital to preserve 
life. An analysis of 4,596 United States military deaths during 
kinetic operations in Iraq and Afghanistan demonstrated that 
87.3% of deaths occurred early, prior to arrival at a medical 
treatment facility. 24.3% of deaths were assessed as potential-
ly survivable had swifter intervention been possible.1 
Non-compressible torso haemorrhage carries a high mortali-
ty, and presents a particular therapeutic challenge as it cannot 
easily be remedied by early medical intervention with pres-
sure dressings, combat tourniquets or haemostatic trauma 
 dressings.2 The only effective therapies for shocked patients 
in this group are early blood component transfusion, whilst 
preparing for emergency laparotomy or thoracotomy in or-
der to gain proximal aortic haemorrhage control, followed by 
damage control surgery. If the patient presents in the peri-ar-
rest phase, outwith a facility capable of providing immedi-
ate surgery, death is likely to ensue. Whilst the presence of 
a full military trauma system proved successful during the 
recent counter-insurgency operations in Afghanistan,3 this 
multi-professional system is difficult to mirror in less mature 
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 contingency operations. Often assembled at relatively short 
notice, casualty evacuation may be hampered by an inability 
to allow air, boat or ground transport assets to be dedicated 
solely for medical transport. Similarly, casualty evacuation 
timelines may be long due to geographical distance, unfavour-
able meteorological variables or tactical issues. Accordingly, 
a haemorrhage control solution that could be deployed into a 
prolonged field care or early in-hospital setting is an attractive 
prospect with life-saving potential due to the ability to buy 
time for surgical haemorrhage control.
Resuscitative endovascular balloon occlusion of the aorta 
(REBOA) is a rapidly evolving solution to haemorrhage con-
trol. It involves occlusion of the descending aorta by delivery 
of a balloon catheter device via an introducer sheath placed in 
the common femoral artery – effectively acting as an endovas-
cular aortic cross-clamp. Three anatomically-defined aortic 
landing zones are described: zone I – thoracic aorta between 
the left subclavian and coeliac artery; zone 2 – between the 
coeliac artery and renal arteries; zone 3 – between the renal 
arteries and aortic bifurcation. Only zones I and III are usu-
ally used as landing zones for emergency haemorrhage con-
trol. Commonly, balloon placement is performed under direct 
fluoroscopic guidance in the emergency department or in a 
hybrid interventional radiology or vascular surgical theatre. A 
small number of cases have been performed in the pre-hospital 
setting by clinicians of London’s Air Ambulance, which de-
ploys a helicopter-delivered, physician-led advanced trauma 
team to the scene of serious incidents.4 
In multiple animal studies, REBOA has been shown to offer 
an effective endovascular solution for severe torso and pelvic 
haemorrhage, resulting in rapid control of bleeding and im-
proved survival, most likely mediated by increased proximal 
blood pressure, brain oxygen delivery and carotid blood flow, 
compared with standard therapy.5-7 In human cohorts, vascu-
lar surgeons have reported the use of balloon occlusion as an 
effective means of gaining rapid haemorrhage control in the 
setting of ruptured aortic aneurysm prior to endovascular re-
pair,8,9 and a number of case series have been reported on the 
use of REBOA in the setting of major traumatic haemorrhage. 
To date, the medical literature contains data on 1355 cases 
treated with REBOA, including reports of non-trauma indica-
tions such as gastrointestinal and post-partum bleeding.10
Outside a resuscitation room equipped with fluoroscopy, with 
which X-ray screening can be used to track the passage of the 
balloon, confirmation of balloon delivery to the intended aor-
tic landing zone presents a significant limitation to REBOA. 
A blind approach is possible, though the potential risk of de-
vice failure or unintentional balloon deployment in a smaller 
branch vessel exists. Trans-abdominal ultrasound techniques 
have been reported, using contrast-enhanced ultrasonography 
to confirm REBOA placement, but these require additional re-
sources and training.11
Intravascular ultrasound (IVUS) is an endovascular imaging 
technique in common use in interventional cardiology and 
radiology. Using a miniaturised, solid-state imaging device 
deployed into the target vessel over a guidewire, it allows 
for real time two-dimensional imaging to be performed. The 
images obtained can be analysed to assess vessel diameter or 
the  burden of atheroma, and to guide interventional therapies 
such as stents. IVUS devices are now small-calibre, simple to 
use and interpret, and are approved by international regulatory 
bodies for use in humans. In interventional cardiology, data 
strongly support IVUS use especially in complex cases, and 
international guidelines recommend their use. 12 ChromaFlo™ 
is an imaging modality which colourises movement in the 
IVUS image pixels as red, presenting a form of 2-dimensional 
Doppler. Pixel movement is thus used as a surrogate for flow, 
and this feature can be used to clearly delineate the vessel lu-
men. This study also aimed to evaluate its use in confirming 
loss of aortic flow following REBOA balloon deployment, as 
a potential tool for evaluating REBOA effect in vivo.
Methods
The study was ethically reviewed, approved, and conducted 
in accordance with the Animals (Scientific Procedures) Act 
1986. Two large white swine, weighing 35kg, were termi-
nally anaesthetised using isoflurane followed by alfaxalone. 
They were instrumented for central and cardiac blood pressure 
measurement, cardiac output measurement and the removal of 
blood and administration of medications and fluids. Following 
the completion of an experimental protocol simulating severe 
haemorrhagic shock followed by damage control resuscita-
tion, the following pilot studies were performed:
Run 1 – IVUS assessment 
To confirm the ability to gain access to and visualise the aorta, 
a 9 French gauge (F) sheath with haemostatic valve and a side 
arm was placed in the right common femoral artery via a lim-
ited cut down to expose the vessel, using a modified Seldinger 
technique under direct vision. Through this, a 175cm, 0.035” 
J-tipped guidewire was passed, over which a 10MHz, 8.5F 
compatible digital IVUS catheter (Visions PV, Philips Volca-
no™) was introduced. The position of the aortic bifurcation 
was visualised under direct IVUS guidance, and the diameter 
of the distal aorta was noted to aid REBOA balloon selection 
for further runs. The IVUS catheter was then removed.
Figure 1: Right femoral access site. Limited cut-down, with 12F 
sheath in femoral artery. REBOA balloon catheter shaft (right of 
picture) and IVUS catheter passing through haemostatic valve. A 
venous sheath is also present.
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Run 2 – ChromaFlo 
Through the femoral sheath, a 0.014” angioplasty guidewire 
(Balance Middle Weight, Abbott™) was introduced into the 
aorta. A hydrophilic-coated 20MHz, 5F compatible digital 
Figure 2: – Tip of combined IVUS-REBOA balloon catheter, with 
balloon deflated. Inset: close-up of IVUS catheter attached to bal-
loon catheter shaft (Eagle Eye Platinum, Philips Volcano™). 
Figure 3: Representative aortic IVUS image. ChromaFlo is activat-
ed, delineating areas of blood flow. A 0.035” guidewire is noted at 
the top of the image as a bright signal, and the inferior vena cava is 
also captured to the left of the aortic signal.
Figure 4: Transduced femoral arterial trace during IVUS-REBOA deployment and deflation. A marked reduction in downstream pressure is 
visible during balloon deployment, which resolves on balloon deflation.
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the contralateral femoral arterial sheath (LabChart, ADI 
 Instruments™).
Run 4 - Combined IVUS-REBOA device 
A bespoke IVUS-REBOA device was fashioned by combin-
ing the angioplasty balloon and the IVUS probe. Multiple 
 REBOA runs were performed, delivering the device through 
the right femoral artery sheath to the distal aorta with Chroma-
Flo active. Once in position, the balloon was deployed, and the 
clinical effect was assessed using both ChromaFlo and obser-
vation of the transduced pressure trace from the contralateral 
femoral arterial sheath.
The position of the balloon from the final run was confirmed 
by direct visualisation of the opened aorta at post-mortem ex-
amination.
IVUS catheter was passed over this (Eagle Eye Platinum, 
Philips Volcano™). Once delivered, ChromaFlo imaging was 
commenced and the image was interpreted.  
Run 3 – ChromaFlo guided REBOA
With the IVUS catheter in situ in the distal aorta, a 9.0*40mm 
angioplasty balloon (Mustang, Boston  Scientific™) was 
passed over a 0.035” guidewire. The balloon was deployed, 
and the aortic flow was monitored using both ChromaF-
lo and observation of the transduced pressure trace from 
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Results
Two pigs were studied in this initial technical evaluation pilot. 
The results of each component are reported. Femoral access 
was gained bilaterally without incident in both subjects.
Run 1 – delivery of the 0.035” guidewire and larger Vision 
catheter was successful at first pass in both cases, and internal 
diameter of the target aortic area was noted as ~10mm. 
Run 2 – delivery of the angioplasty guidewire and Eagle Eye 
catheter was successful at first pass in both cases. Chroma-
Flow imaging clearly delineated the aortic wall, and confirmed 
pulsatile flow in time with the cardiac cycle and corresponding 
to the transduced arterial pressure traces. Even in the setting of 
cardiac arrest with chest compressions underway (according 
to study protocol) by a mechanical cardiopulmonary resusci-
tation device (LUCAS 2, Physio Control™), ChromaFlo was 
able to detect the presence of aortic flow. 
Run 3 – delivery of the REBOA guidewire and balloon was suc-
cessful at first pass, and easily visualised using live IVUS imag-
ing, with both guidewire and balloon shafts visible as they passed 
the IVUS catheter. In addition, on deployment of the REBOA 
balloon, ChromaFlo pulsation was lost simultaneously with a 
dramatic reduction in transduced distal arterial pressure trace.
Run 4 – delivery of the IVUS-REBOA device was success-
ful at first pass in all cases (total 10 runs). IVUS imaging 
confirmed correct deployment of the device above the iliac 
bifurcation, in aortic zone 3. ChromaFlo imaging confirmed 
full apposition of the REBOA balloon to the aortic wall, and 
loss of pulsatile signal confirmed aortic occlusion, again cor-
responding with loss of transduced distal arterial pressure 
trace. On deflating the REBOA balloon, forward flow rapidly 
re-established, confirmed by restoration of a visible pulsatile 
ChromaFlo signal and transduced distal arterial pressure trace. 
The mean time taken from balloon insertion into the femoral 
sheath to balloon deployment was 21.25 seconds (n=10 runs, 
range 18.1-24.0 seconds). 
Post-mortem examination confirmed correct delivery of the 
IVUS-REBOA device to the distal aortic landing zone in both 
subjects. No vascular injuries related to either vascular access 
or REBOA were found. 
Discussion 
This series of studies demonstrates, for the first time in a por-
cine model, that a commercially available IVUS catheter can 
be used to confirm delivery of the REBOA balloon to the cor-
rect anatomical landing area. It also allows real-time obser-
vation of balloon deployment and confirms apposition of the 
balloon to the vessel wall. The addition of ChromaFlo imaging 
allowed confirmation of loss of pulsatile aortic flow distal to 
the deployed balloon, confirming clinical effect. Deployment 
of the device was rapid, safe and did not require fluoroscopy. 
Limitations
This was a proof-of-concept pilot study, hence the number of 
animal subjects was small. An expanded study using a nov-
el pressurised human cadaveric model is planned. The fem-
oral access devices used were relatively large (9-12F) due to 
the calibre required to introduce the IVUS catheter as a pig-
gy-backed device coupled to the REBOA balloon. If a com-
bined device were to be manufactured, with a lower cross-sec-
tional profile, a smaller femoral sheath could be used. A recent 
multicentre registry study confirms that the use of smaller 
sheaths is associated with fewer access site complications, 
such as thrombus and distal ischaemia.13 The use of smaller 
sheaths (e.g. 7F) is likely to broaden REBOA delivery among 
physicians who are not regular endovascular operators. In 
Figure 5: Commercially available REBOA device (ER-REBOA™ catheter, image courtesy of Prytime Medical) for comparison, with balloon 
deployed.
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 addition, the use of vascular access sites other than the femoral 
area is attractive, especially following trauma where the groin 
might be anatomically disrupted and involved in the primary 
injury. Interventional cardiology procedures, using catheters 
most commonly 6F, but ranging from 5-7.5F, predominantly 
use the radial artery as the primary access site of choice, due 
to lower procedural access site related complications. REBOA 
from non-femoral sites has been reported, but confirmation 
of delivery to the intended target landing zone would usual-
ly mandate fluoroscopy. Forward-looking, three-dimensional 
IVUS, currently an investigative tool, might offer a solution 
to this, allowing the operator to steer the aortic balloon from 
the subclavian system into the descending aorta, and on to the 
intended landing zone. Staying away from the femoral site 
would also reduce procedural complications such as pseu-
doaneurysm formation, the development of arteriovenous fis-
tulae and post-procedural bleeding. Care of the radial access 
site is also much easier, using direct pressure with a currently 
available compression band device (e.g. TR band, Terumo™).
IVUS imaging requires connection of the endovascular part of 
the catheter to an external processing unit via a connector ca-
ble. This is currently built solely for in-hospital use in the inter-
ventional suite, and is a wheeled tower containing a processing 
unit and a display screen. Whilst the current unit could be suit-
able for emergency department-delivered IVUS- REBOA, it 
would require extensive miniaturisation to enable its use in the 
pre-hospital setting. Ultrasound devices using wireless probes 
such as the Accuson Freestyle™ have already been used by 
military units in austere settings,14 and the development of a 
combined IVUS-REBOA device which connects wirelessly to 
a handheld tablet-sized screen could easily be achieved and 
make this a therapy which is truly suited to pre-hospital and 
prolonged field care situations. Most critical care clinicians 
are used to interpreting ultrasound images, and little additional 
training uplift would be required to interpret IVUS images.
REBOA has the potential to save lives in a military trauma co-
hort. Retrospective analysis of a UK military cohort identified 
174 combat deaths due to exsanguinating trauma, with a mean 
pre-hospital time of 61 minutes.7 66 deaths occurred en route to 
hospital, and 29 shortly after arrival at the receiving facility. From 
injury analysis, 20% of patients had a focus of haemorrhage in 
the abdomen or around the abdomino-pelvic junction that could 
have been anatomically controlled with REBOA. It is likely that 
a significant number of the remainder could also have benefitted 
from the physiological stabilisation offered by REBOA.7 A pop-
ulation-based gap analysis of civilian trauma patients in England 
and Wales revealed similar data and suggested a role for REBOA 
mostly within high volume major trauma centres.15 REBOA is 
now well established as a potential therapy for exsanguinating 
trauma, which could significantly improve outcomes in critically 
ill patients for whom there are no viable options. REBOA, as 
part of an armoury of advanced endovascular techniques, may 
be ready for exploitation when planning deployed damage con-
trol resuscitation and surgery facilities for military operations.16 
Potential UK military uses might include Role 2 units, especially 
where surgical capacity is limited to one operating table, and a 
potential requirement might exist to stabilise one patient whilst 
another undergoes damage control surgery. This would include 
the Royal Navy Role 2 Afloat, and Commando Forces Surgical 
Group Role 2 Light Manoeuvre units.
IVUS-REBOA could also help to mitigate downstream tissue 
ischaemia. With the REBOA balloon totally inflated, down-
stream haemorrhage stops. Unfortunately, this results in an ac-
cumulation of metabolites in downstream tissues. Long periods 
of balloon inflation have been shown to result in a rise in lac-
tate, interleukin-6, an increased vasopressor requirement and 
respiratory distress syndrome.17 Partial REBOA (pREBOA), 
with subtotal aortic occlusion which allows a limited amount 
of forward flow, can be used to extend the therapeutic window 
as demonstrated in recent animal studies. pREBOA results 
in reduced levels of serum lactate, with reduced splanchnic 
injury, when compared with complete REBOA (cREBOA), 
and also avoids the supra-normal pressure surge seen in the 
vascular tree above the inflated REBOA balloon.18 pREBOA 
thus offers a physiologically and haemodynamically tolerable 
option for endovascular haemorrhage control, which might 
extend the golden hour after traumatic injury.19 Pragmatically, 
an initial cREBOA inflation, to rapidly achieve control is ad-
vocated. Following this, pREBOA could be considered, sup-
ported by registry data which further suggests that pREBOA 
is associated with better outcomes in human subjects.13 Clin-
ically, there is no easy way to confirm whether cREBOA or 
pREBOA has been achieved. IVUS imaging offers a solution 
to this, allowing direct visualisation of balloon apposition to 
the vessel wall, allowing the operator to see whether complete 
or partial occlusion has been performed. ChromaFlo imaging 
would allow the operator to visualise a degree of forward flow 
should pREBOA be desired. Further research is required to 
assess the optimum degree of forward flow, and it is likely that 
this will vary between patients. An endovascular variable aor-
tic control (EVAC) system, regulating the degree of REBOA 
based on changes in proximal pressure has been trialled in an 
animal study,20 and IVUS-REBOA technology could have a 
role in developing future variants of such an EVAC catheter, 
able to automatically perform these functions. 
IVUS could be part of an advanced endovascular resuscita-
tion toolkit. As part of an advanced endovascular resuscitation 
strategy, REBOA offers a bridge to damage control surgery. If 
traumatic cardiac arrest ensues, access to the aorta gives the 
added advantage of allowing future therapies such as selective 
aortic arch perfusion using either oxygenated blood or novel 
resuscitation fluids.21 If initial efforts still fail, the addition of a 
large-bore venous cannula would make full cardiopulmonary 
bypass possible following damage control surgery. This com-
bination of techniques – emergency preservation and resusci-
tation (EPR) and resuscitation for cardiac arrest from trauma 
is currently undergoing a feasibility and safety study in the 
United States (EPR-Cat study; ClinicalTrials.gov identifier 
NCT01042015). It is likely, as data emerges, that REBOA, 
SAAP and EPR will overlap to form a hybrid advanced endo-
vascular toolkit for the management of haemorrhagic shock.22 
Developing a robust REBOA capability is the first step to en-
abling deployed damage control resuscitation teams to be able 
to exploit these techniques as the data emerges in future. 
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